Eli Lilly’s AtaiBeckley acquisition marks a dozen M&A offers for the pharma firm up to now this 12 months. AtaiBeckley’s lead program is an intranasally administered psychedelic drug in pivotal testing for treatment-resistant despair.
The put up Lilly Expands Its Thoughts to Psychedelics With $2.8B AtaiBeckley Acquisition appeared first on MedCity Information.
